{"contentid": 488684, "importid": NaN, "name": "Numab completes oversubscribed $110 million financing", "introduction": "Swiss clinical-stage biotech Numab Therapeutics today announced the closing of a 100 million Swiss franc (~$110 million) Series C financing.", "content": "<p>Swiss clinical-stage biotech Numab Therapeutics today announced the closing of a 100 million Swiss franc (~$110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors.</p>\n<p>Concurrent with the financing, Nanna L&uuml;neborg from Novo Ventures, Matthias Fehr from HBM Partners, and Carlo Incerti from Forbion have been appointed to Numab&rsquo;s board of directors.</p>\n<p>Proceeds will support acceleration and expansion of the clinical development of Numab&rsquo;s lead program NM21-1480 into multiple cancer indications, and the advancement of the company&rsquo;s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.</p>\n<p>Numab, which last year lured former Novartis chief Daniel Vasella to be its chairman, already has a number of licensing deal with various pharma majors, including Japan&rsquo;s Ono Pharmaceutical (TYO: 4528) and Eisai (TYO: 4523), as well as Germany&rsquo;s Boehringer Ingelheim.</p>\n<h2><strong>Lead compound NM21-1480 has best-in-class potential</strong></h2>\n<p>&ldquo;We are thrilled to be supported by such a strong group of investors who share our vision for the company&rsquo;s future,&rdquo; said David Urech, founder and chief executive of Numab Therapeutics. &ldquo;Combining PD-L1 blockade with tumor localized 4-1BB co-stimulation in a single molecule emerges as an attractive next-generation therapeutic strategy in solid tumors, and Numab&rsquo;s lead compound NM21-1480 has best-in-class potential. The financing will help us to maximize the value of this asset by significantly expanding the clinical development program and accelerating toward Phase II proof-of-concept.&rdquo;</p>\n<p>&ldquo;We are impressed by the biological insights that went into the engineering of NM21-1480 and by the innovative pipeline that Numab has established. We believe that Numab&rsquo;s innovative Lambda-cap and MATCH technologies can provide treatment options with favorable benefit-to-risk profiles,&rdquo; said Matthias Fehr, head private equity at HBM Partners.</p>\n<p>Additional new investors were Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners, RTW Investments, funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.</p>\n<p>&nbsp;</p>", "date": "2021-05-20 11:37:00", "meta_title": "Numab completes oversubscribed $110 million financing", "meta_keywords": "Numab Therapeutics, Financing, Series C, Research, Lead compound, NM21-1480", "meta_description": "Numab completes oversubscribed $110 million financing", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-20 11:36:37", "updated": "2021-05-20 11:44:44", "access": NaN, "url": "https://www.thepharmaletter.com/article/numab-completes-oversubscribed-110-million-financing", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "numab_big.png", "image2id": "numab_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Business Financing, Management, One to Watch Companies, Research", "geography_tag": "Switzerland", "company_tag": "Novo Holdings, Numab", "drug_tag": "NM21-1480", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-20 11:37:00"}